Navigation Links
Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing
Date:3/31/2008

States in the absence of an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the convertible preferred stock.

About ARIKACE (liposomal amikacin for inhalation)

ARIKACE is a form of the antibiotic amikacin that is enclosed in nanocapsules of lipid called liposomes. This proprietary next-generation liposomal technology prolongs release of amikacin in the lung while minimizing systemic exposure. The treatment uses biocompatible lipids endogenous to the lung that are formulated into small (0.3 mm) neutrally charged liposomes that enable biofilm penetration and are highly efficient with very low lipid to drug ratio (0.6). ARIKACE can be effectively delivered through nebulization where the small aerosol droplet size (~3.0 mm) facilitates lung distribution. Two Phase II studies are currently being conducted in patients that have CF and Pseudomonas lung infections in Europe and the United States. An abstract on the top line European Phase II data in CF has been accepted for presentation at the 31st European Cystic Fibrosis Conference in Prague in June. ARIKACE has been granted orphan drug status in the United States by the FDA and orphan drug designation in Europe by the European Medicines Agency (EMEA) for the treatment of Pseudomonas infections in patients with CF.

About Transave Inc.

Transave Inc is a biopharmaceutical company focused on the development of innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases. The company's major focus is developing antibiotic therapy delivered via next-generation liposomal technology in areas of high unmet need in respiratory disease. Transave is dedicated to leveraging its advanced liposomal development and commercialization expertise, along with its intellectual property, to bring life extending and enhanc
'/>"/>

SOURCE Transave, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round
2. Moodys Raises Rating for Gerresheimer
3. SleepQuest Raises Awareness of Sleep Disorders
4. Arthrosurface Raises $4 Million of Preferred Equity Financing
5. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
6. Skystar Bio-Pharmaceutical Raises 2007 Revenue Guidance to $15.8 Million
7. Circassia Raises GBP11 Million ($21.8 Million) in Oversubscribed Second Round Funding
8. Primera Biosystems Raises $21 Million in Series B Private Round
9. Cellectar, Inc. Raises $13 Million in Private Offering
10. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic
11. Anesiva Raises $45 Million in Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Hershey, PA (PRWEB) December 19, 2014 ... a leading developer and manufacturer of needle-free injection ... an agreement with Immunomic Therapeutics, Inc. (“ITI”) for ... injection device with its LAMP™ vaccine platform. ... for an exclusive Worldwide license to the Biojector®-2000 ...
(Date:12/19/2014)... 2014 BioPlus Specialty Pharmacy ... the promotion of Nick Maroulis, Pharm.D. to the newly ... , In this position, Dr. Maroulis will continue ... the directors of our multi-site pharmacies as the company ... and during that time he has served in many ...
(Date:12/19/2014)... PLEASANTON, Calif. , Dec. 19, 2014  Roche ... acquisition of Bina Technologies, Inc. (Bina), a privately ... California , USA. Bina provides a big ... next generation sequencing (NGS) data. Bina,s proprietary on-market ... translational and academic researchers to perform fast and ...
(Date:12/19/2014)... 2014 Decision Resources Group finds that the ... 12 percent compound annual growth rate through 2023. This ... and the increasing adoption of dental implants. Growing aesthetic ... also spur demand for dental biomaterials because they can ... treatments. Other key findings from Decision Resources ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... June 30 TargeGen, Inc., a privately held ... inhibitors today announced that the Company has agreed to be ... the ultimate purchase price will depend on the achievement of ... if such milestones are fully realized. The closing of the ...
... June 30 /PRNewswire/ - Sirius Genomics, a developer of ... appointed Senior Director of Business Development. , ... "Sirius Genomics is on track with our ... in partnering with both global pharmaceutical and medical device companies as ...
... 30 SeqWright Inc., a world-wide leader ... today the expansion of its service portfolio by ... innovative RainStorm™ microdroplet-based PCR technology.  SeqWright recognizes the ... efficient and cost-effective processes that allow for automated ...
Cached Biology Technology:Sanofi-aventis to Acquire TargeGen, Inc. 2Sirius Genomics Announces Appointment of Senior Director of Business Development 2SeqWright Expands Genomics Services Offering Through New Partnership With RainDance Technologies 2
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
(Date:12/10/2014)... Dec. 9, 2014  Wake Forest Baptist Medical Center today ... its School of Medicine. Funding for this $50 million ... that will be publicly launched next summer. ... the former 60 series R.J. Reynolds Tobacco Company complex, ... will begin immediately with plans to be ready to ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4
... University researcher has identified the important role that a ... could lead to a greater understanding of stem cells. ... College of Medicine, has outlined his findings in the ... Developmental Cell . The article, "CDK5RAP2 Regulates Centriole Engagement ...
... two-thirds of toxic lead that African-American children in Cleveland ... 20th century, according to a new study in ... Case Western Reserve University say what they,ve shown in ... and reinforces concerns about the health threat for children ...
... has been one of the nation,s premier outlets for stories ... professor has put many of those stories together in a ... Though intended for the classroom, Discover magazine blogger Carl Zimmer, ... collection, The New York Times Reader -- Science and ...
Cached Biology News:Florida State researcher uncovers protein's role in cell division 2Leaded gasoline predominant source of lead exposure in latter 20th century 2Leaded gasoline predominant source of lead exposure in latter 20th century 3IU professor's new textbook uses the best science writing from the New York Times 2IU professor's new textbook uses the best science writing from the New York Times 3
...
... The Agilent 6850 Networked GC is an ... the footprint of a standard dual-channel GC, this ... two GCs in the space of one. You ... for routine GC analyses in an instrument that ...
... GC-8A is Shimadzu's basic gas chromatograph model ... use, the GC-8A supports a single detector, ... injection port(s), and analog output. Isothermal or ... The GC-8A is only 17.3 inches (43.9 ...
... laboratory animal infusion kits reduce the time ... study while providing sterile equipment to reduce ... everything you need for one animal, including ... tethers will be cut to the exact ...
Biology Products: